Cue Biopharma downsizes to focus on autoimmune pipeline
Cue Biopharma has instituted strategic restructuring measures with a plan to focus on autoimmune programmes and carry out a workforce…
Cue Biopharma has instituted strategic restructuring measures with a plan to focus on autoimmune programmes and carry out a workforce…
Ipsen is looking to expand its paediatric medication portfolio and has signed a licensing agreement potentially worth $461m with Day…
Dren Bio has partnered strategically with Novartis subsidiary Novartis Pharma to discover and develop therapeutic bispecific antibodies to treat cancer.…
A day after announcing a $400m convertible bond offering, Telix Pharmaceuticals has had a new drug application (NDA) accepted by…
AstraZeneca has signed a licensing agreement with Pinetree Therapeutics for a preclinical epidermal growth factor receptor (EGFR) degrader candidate, potentially…
Not long after pulling a last-minute plug on a $232m initial public offering (IPO) on Nasdaq, Telix Pharmaceuticals has raised…
The UK National Institute for Health and Care Excellence (NICE) has recommended Accord's Relugolix (Orgovyx), as a treatment for advanced…
The European Medicines Agency (EMA) has accepted for review GSK’s marketing authorisation application (MAA) for Blenrep (belantamab mafodotin), an antibody-drug…
Exscientia has taken full ownership of an oral cyclin-dependent kinase 7 (CDK7) inhibitor after buying out its development partner GT…
The European Medicines Agency (EMA) has accepted for review the marketing authorisation application (MAA) of Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals'…